JAK2 and acute lymphoblastic leukemia: The high specificity of fedratinib for JAK2 suggests that it may associate with less dose-limiting toxicity in comparison to ruxolitinib and therefore, may be a more efficacious JAK inhibitor for the treatment of JAK2-altered ALL when used in combination with chemotherapy.